SCHOLAR ROCK HOLDING CORPORATION Increase (Decrease) in Accounts Payable
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Increase (Decrease) in Accounts Payable of $665.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $1.75M.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.08M.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $3.54M, a 41.25% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $5.66M, a 648.68% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts payable for fiscal 2025 was $208.00K, a 96.86% decline from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts payable for fiscal 2024 was $6.63M.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts payable for fiscal 2023 was -$529.00K.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in accounts payable for fiscal 2022 was -$251.00K, a 124.70% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $665.00K 10-Q · filed 2026-08-06 | $4.20M derived: sum of 3 quarters · filed 2026-08-06 | $9.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.08M 10-Q · filed 2026-05-07 | $2.45M derived: sum of 2 quarters · filed 2026-05-07 | $8.11M derived: sum of 3 quarters · filed 2026-05-07 | $4.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $9.20M derived: sum of 2 quarters · filed 2026-03-03 | $5.87M derived: sum of 3 quarters · filed 2026-08-06 | $208.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | $5.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.33M derived: sum of 2 quarters · filed 2026-08-06 | -$3.33M 10-Q · filed 2025-11-14 | $2.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$3.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$8.99M 10-Q · filed 2026-08-06 | -$2.97M derived: sum of 3 quarters · filed 2026-08-06 | -$2.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$5.66M 10-Q · filed 2026-05-07 | $366.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.12M derived: sum of 3 quarters · filed 2026-05-07 | $1.58M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $6.78M derived: sum of 2 quarters · filed 2026-03-03 | $7.24M derived: sum of 3 quarters · filed 2026-03-03 | $6.63M 10-K · filed 2026-03-03 |
| 2024-09-30 | $756.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.22M derived: sum of 2 quarters · filed 2025-11-14 | $606.00K 10-Q · filed 2025-11-14 | $2.10M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $460.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$150.00K 10-Q · filed 2025-08-06 | $1.35M derived: sum of 3 quarters · filed 2025-08-06 | $271.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$610.00K 10-Q · filed 2025-05-14 | $887.00K derived: sum of 2 quarters · filed 2025-05-14 | -$189.00K derived: sum of 3 quarters · filed 2025-05-14 | -$865.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $421.00K derived: sum of 2 quarters · filed 2025-02-27 | -$255.00K derived: sum of 3 quarters · filed 2025-02-27 | -$529.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.75M derived: sum of 2 quarters · filed 2024-11-12 | -$2.03M 10-Q · filed 2024-11-12 | -$32.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$676.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$950.00K 10-Q · filed 2024-08-08 | $1.04M derived: sum of 3 quarters · filed 2024-08-08 | $193.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$274.00K 10-Q · filed 2024-05-07 | $1.72M derived: sum of 2 quarters · filed 2024-05-07 | $869.00K derived: sum of 3 quarters · filed 2024-05-07 | $1.05M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $1.14M derived: sum of 2 quarters · filed 2024-03-19 | $1.33M derived: sum of 3 quarters · filed 2024-03-19 | -$251.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | -$851.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$665.00K derived: sum of 2 quarters · filed 2023-11-07 | -$2.25M 10-Q · filed 2023-11-07 | -$35.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $186.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.39M 10-Q · filed 2023-08-09 | $816.00K derived: sum of 3 quarters · filed 2023-08-09 | $1.40M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$1.58M 10-Q · filed 2023-05-09 | $630.00K derived: sum of 2 quarters · filed 2023-05-09 | $1.22M derived: sum of 3 quarters · filed 2023-05-09 | $664.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $2.79M derived: sum of 2 quarters · filed 2023-03-07 | $2.24M derived: sum of 3 quarters · filed 2023-03-07 | $1.02M 10-K · filed 2023-03-07 |
| 2021-09-30 | $585.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $34.00K derived: sum of 2 quarters · filed 2022-11-14 | -$1.19M 10-Q · filed 2022-11-14 | $931.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$551.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$1.78M 10-Q · filed 2022-08-08 | $346.00K derived: sum of 3 quarters · filed 2022-08-08 | -$1.22M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$1.23M 10-Q · filed 2022-05-16 | $897.00K derived: sum of 2 quarters · filed 2022-05-16 | -$670.00K derived: sum of 3 quarters · filed 2022-05-16 | -$216.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $558.00K derived: sum of 2 quarters · filed 2022-03-07 | $1.01M derived: sum of 3 quarters · filed 2022-03-07 | $2.10M 10-K · filed 2022-03-07 |
| 2020-09-30 | -$1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$1.11M derived: sum of 2 quarters · filed 2021-11-09 | -$24.00K 10-Q · filed 2021-11-09 | -$702.00K derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $454.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $1.54M 10-Q · filed 2021-08-10 | $865.00K derived: sum of 3 quarters · filed 2021-08-10 | $1.23M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $1.09M 10-Q · filed 2021-05-13 | $411.00K derived: sum of 2 quarters · filed 2021-05-13 | $775.00K derived: sum of 3 quarters · filed 2021-05-13 | -$155.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$678.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$314.00K derived: sum of 2 quarters · filed 2021-03-09 | -$1.24M derived: sum of 3 quarters · filed 2021-03-09 | -$1.34M 10-K · filed 2021-03-09 |
| 2019-09-30 | $364.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$566.00K derived: sum of 2 quarters · filed 2020-11-09 | -$664.00K 10-Q · filed 2020-11-09 | $706.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$930.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$1.03M 10-Q · filed 2020-08-07 | $342.00K derived: sum of 3 quarters · filed 2020-08-07 | $172.00K derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | -$98.00K 10-Q · filed 2020-05-07 | $1.27M derived: sum of 2 quarters · filed 2020-05-07 | $1.10M derived: sum of 3 quarters · filed 2020-05-07 | $37.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $1.20M derived: sum of 2 quarters · filed 2020-03-12 | $135.00K derived: sum of 3 quarters · filed 2020-03-12 | $1.66M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$1.24M derived: sum of 2 quarters · filed 2019-11-12 | $294.00K 10-Q · filed 2019-11-12 | -$726.00K derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | -$1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $464.00K 10-Q · filed 2019-08-14 | -$556.00K derived: sum of 3 quarters · filed 2019-08-14 | $462.00K derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $1.53M 10-Q · filed 2019-05-15 | $509.00K derived: sum of 2 quarters · filed 2019-05-15 | $1.53M derived: sum of 3 quarters · filed 2019-05-15 | |
| 2017-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | -$2.00K derived: sum of 2 quarters · filed 2019-03-19 | $636.00K 10-K · filed 2019-03-19 | |
| 2017-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.66M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $638.00K 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |